Rheumnow Podcast
By Dr. Cush
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Episodes (7)
Rheumnow Podcast
EULAR 2026 Daily Podcast Day 1a
A groundbreaking study presented at EULAR 2026 reveals that rheumatoid arthritis fundamentally alters body composition in ways conventional metrics like BMI fail to detect—patients show increased intermuscular fat and reduced muscle quality (myosteatosis), eve
Rheumnow Podcast
EULAR 2026 Daily Podcast Day 2a
A groundbreaking study using Gallium-68 PET scans reveals that nearly half of psoriatic arthritis patients with no visible joint swelling or tenderness still show significant subclinical inflammation—detectable through molecular imaging of angiogenesis. This c
Rheumnow Podcast
Daily Recap Day 1 + 2 EULAR 2026
A groundbreaking study presented at EULAR 2026 reveals that letting patients choose their rheumatoid arthritis (RA) biologic therapy—via a simple three-minute educational video—leads to significantly higher treatment satisfaction, better retention, and fewer a
Rheumnow Podcast
EULAR 2026 Daily Podcast Day 2c
A groundbreaking head-to-head trial at EULAR 2026 reveals that bimikizumab—dual IL-17A and IL-17F inhibition—significantly outperforms risankizumab (IL-23 inhibitor) in psoriatic arthritis, with 50% achieving ACR50 at week 16 versus 38%. This clear superiority
Rheumnow Podcast
Day 3 Recap EULAR 2026
The Rheumnow Podcast's Day 3 recap from EULAR 2026 in London delivers a sharp, candid critique of the conference's research output, with host Jack Kush bluntly calling the day 'pretty weak'—not for lack of educational content, but for a dearth of novel, high-i
Rheumnow Podcast
EULAR 2026 Daily Podcast Day 3a
A groundbreaking study presented at EULAR 2026 reveals that digital patient education for newly diagnosed rheumatoid arthritis patients is not only as effective as traditional face-to-face instruction but also reduces healthcare costs by €500–600 per patient a
Rheumnow Podcast
Day 4 Recap EULAR 2026
A landmark study on baricitinib in early polymyalgia rheumatica (PMR) shows a dramatic 65% glucocorticoid-free remission rate at 16 weeks—nearly four times higher than placebo—suggesting JAK inhibitors could revolutionize steroid-sparing therapy. Yet, the data
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime